Human Vaccines Administered Orally Market

Oral vaccines are safe and easy to administer and convenient for all ages. They have been successfully developed to protect from many infectious diseases acquired through oral transmission. Oral delivery of vaccines represents the most attractive mode of administration over other routes of delivery due to the fact that the oral vaccination is noninvasive, safe and simple to execute, showing good patient compliance and clinical practicality.
Human Vaccines Administered Orally Market contains market size and forecasts of Human Vaccines Administered Orally in global, including the following market information:
Global Human Vaccines Administered Orally Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Human Vaccines Administered Orally Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Human Vaccines Administered Orally companies in 2021 (%)
The global Human Vaccines Administered Orally market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Rotavirus Vaccine Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Human Vaccines Administered Orally include Merck, GSK, Sanofi, Lanzhou Institute, Serum Institute, Valneva, Shanghai United Cell, Bibcol and PaxVax, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Human Vaccines Administered Orally manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Human Vaccines Administered Orally Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Vaccines Administered Orally Market Segment Percentages, by Type, 2021 (%)
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Global Human Vaccines Administered Orally Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Vaccines Administered Orally Market Segment Percentages, by Application, 2021 (%)
Public
Private
Global Human Vaccines Administered Orally Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Human Vaccines Administered Orally Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Human Vaccines Administered Orally revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Human Vaccines Administered Orally revenues share in global market, 2021 (%)
Key companies Human Vaccines Administered Orally sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Human Vaccines Administered Orally sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals